VJRegenMed is committed to improving our service to you

Share this video  

VJRegenMed is committed to improving our service to you

Advanced Therapies Week 2022 | Looking forward to Advanced Therapies Week 2022

Janet Lynch Lambert, CEO, Alliance for Regenerative Medicine, Washington, D.C., shares her excitement towards meeting colleagues and learning about the latest scientific advances at the Advanced Therapies Week 2022, in particular in in vivo gene editing and in vivo chimeric antigen receptor (CAR) T-cells. This interview took place at Advanced Therapies Week 2022.

Disclosures

Janet Lynch Lambert is the CEO of Alliance for Regenerative Medicine.